Table 1.
Baseline Characteristics
| Characteristic | NT-proBNP guided (n=446) |
Usual care (n=448) |
|---|---|---|
| Age (years) median [25th–75th] | 62 [51,70] | 64 [54,72] |
| Sex, No (% female) | 139 (31%) | 147 (33%) |
| Race, No (%) | ||
| White | 230 (54%) | 260 (59%) |
| Black | 168 (39%) | 156 (35%) |
| Other | 35 (7%) | 26 (6%) |
| Ethnicity, No. (% Hispanic) | 30 (7%) | 28 (6%) |
| Duration of HF (months) median [25th–75th] | 12 [1, 65] | 16 [1, 61] |
| Ejection fraction (%) median [25th–75th] | 24 [19,30] | 25 [20,30] |
| NYHA class at enrollment, No (%) | 36 (8%) | 23 (5%) |
| I | 218 (50%) | 229 (52%) |
| II | 176 (40%) | 182 (41%) |
| III | 8 (2%) | 9 (2%) |
| IV | ||
| History of: No,(%) | ||
| Ischemic heart disease | 203 (46%) | 244 (55%) |
| Diabetes mellitus | 198 (44%) | 212 (47%) |
| Atrial fibrillation | 162 (36%) | 196 (44%) |
| Chronic kidney disease | 161 (36%) | 169 (38%) |
| Systolic BP(mmHg) median [25th–75th] | 114 [102,128] | 114 [101,128] |
| Heart rate (beats/min) median [25th–75th] | 77 [68,87] | 76 [67,86] |
| NT-proBNP (pg/mL) median [25th–75th] | 2632 [1462–5235] | 2668 [1481–5604] |
| Creatinine (mg/dL) median [25th–75th] | 1.3 [1.1,1.7] | 1.3 [1.1,1.7] |
| Beta-blocker, No. (%) | 415 (93%) | 416 (93%) |
| Angiotensin Converting Enzyme inhibitor, Angiotensin receptor blocker, or Angiotensin receptor blocker neprilysin inhibitor, No. (%) | 345 (77%) | 339 (76%) |
| Mineralocorticoid antagonist (%) No. (%) | 223 (50%) | 217 (48%) |
| Implantable cardioverter defibrillator (%) No (%) | 182 (41%) | 178 (40%) |
| Cardiac resynchronization therapy No (%) | 87 (20%) | 76 (17%) |